We are live on ! Find out more
Birchview Capital

Birchview Capital Portfolio holdings

AUM $173M Turnover 41.05%
1-Year Est. Return 89.27%
This Fund
S&P 500
This Quarter Est. Return
-16.77%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$140M
AUM Growth
-$33.4M
Cap. Flow
+$24.5K
Cap. Flow %
0.02%
Top 10 Hldgs %
90.94%
Holding
43
New
3
Increased
9
Reduced
4
Closed
3
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.9 years

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Energy 3.24%
3 Consumer Staples 2.76%
4 Miscellaneous 2.08%
5 Technology 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$78M 55.59%
779,051
+2,700
+0.3% +$278K
2014 Q4
5 quarters
AXDX icon
2
DELISTED
Accelerate Diagnostics
AXDX
$31.3M 22.29%
217,580
+2,000
+0.9% +$282K
2014 Q4
5 quarters
VRML
3
DELISTED
Vermillion
VRML
$4M 2.85%
2,717,514
– –
2014 Q4
5 quarters
YTEN icon
4
DELISTED
Yield10 Bioscience
YTEN
$3.87M 2.76%
236
– –
2014 Q4
5 quarters
EQT icon
5
EQT
EQT
$30.8B
$2.84M 2.03%
77,705
– –
2014 Q4
5 quarters
BIOL icon
6
DELISTED
Biolase
BIOL
$1.68M 1.2%
103
– –
2014 Q4
5 quarters
CFRX
7
DELISTED
ContraFect
CFRX
$1.62M 1.15%
594
– –
2015 Q2
3 quarters
MASI icon
8
DELISTED
Masimo
MASI
$1.53M 1.09%
36,600
– –
2014 Q4
5 quarters
COLL icon
9
Collegium Pharmaceutical
COLL
$783M
$1.39M 0.99%
76,768
+18,000
+31% +$327K
2015 Q2
3 quarters
HNSN
10
DELISTED
Hansen Medical
HNSN
$1.38M 0.98%
528,142
-1
-0% -$2
2014 Q4
5 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.8B
$997K 0.71%
25,200
+2,000
+9% +$79.4K
2015 Q3
2 quarters
MDVN
12
DELISTED
Medivation
MDVN
$863K 0.62%
18,760
-14,000
-43% -$508K
2014 Q4
5 quarters
OVV icon
13
Ovintiv
OVV
$16.5B
$806K 0.57%
26,460
– –
2014 Q4
5 quarters
MRK icon
14
Merck
MRK
$327B
$794K 0.57%
15,720
– –
2014 Q4
5 quarters
OMED
15
DELISTED
OncoMed Pharmaceuticals
OMED
$715K 0.51%
70,689
+12,000
+20% +$141K
2014 Q4
5 quarters
QDEL icon
16
QuidelOrtho
QDEL
$612M
$673K 0.48%
38,975
– –
2014 Q4
5 quarters
OXFD
17
DELISTED
Oxford Immunotec Global
OXFD
$558K 0.4%
56,303
+16,000
+40% +$164K
2015 Q3
2 quarters
ARAY icon
18
Accuray
ARAY
$6.36M
$551K 0.39%
2,383
– –
2014 Q4
5 quarters
QTNT
19
DELISTED
Quotient Ltd
QTNT
$512K 0.37%
1,455
– –
2014 Q4
5 quarters
WMGI
20
DELISTED
Wright Medical Group
WMGI
$498K 0.36%
30,000
– –
2015 Q4
1 quarter
CTRA icon
21
DELISTED
Coterra Energy
CTRA
$477K 0.34%
21,000
– –
2014 Q4
5 quarters
SIEN
22
DELISTED
Sientra
SIEN
$433K 0.31%
6,330
– –
2015 Q3
2 quarters
NXTM
23
DELISTED
NxStage Medical
NXTM
$423K 0.3%
28,200
+2,500
+10% +$41.9K
2014 Q4
5 quarters
PXD icon
24
DELISTED
Pioneer Natural Resources
PXD
$422K 0.3%
3,000
– –
2014 Q4
5 quarters
CORT icon
25
Corcept Therapeutics
CORT
$7.02B
$374K 0.27%
80,000
– –
2015 Q4
1 quarter

Similar funds

Birchview Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Birchview Capital held 43 positions worth $140M, down 19% from $174M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q1 2016 filing shows 3 new, 9 increased, 4 reduced and 3 closed positions. Its largest new stake was Pacific Biosciences: 27,000 shares worth $230K. The largest sale was Medivation, an estimated $508K.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2016 buy was Pacific Biosciences: 27,000 shares worth $230K.
  • Birchview Capital added most to Collegium Pharmaceutical in Q1 2016, an estimated $327K increase.
  • Birchview Capital's biggest Q1 2016 reduction was Medivation, cutting an estimated $508K.
  • Birchview Capital fully exited PTC Therapeutics in Q1 2016, selling an estimated $483K.
  • Birchview Capital's ten largest holdings make up 91% of its $140M portfolio in Q1 2016.
  • Birchview Capital opened 3 new positions and closed 3 in Q1 2016.
  • Birchview Capital's portfolio value fell 19% quarter-over-quarter to $140M.

Based on Birchview Capital's 13F filing for Q1 2016, filed 28 Apr 2016.